Vaccine manufacturer Moderna has welcomed the Chancellor's announcements regarding major infrastructure schemes.

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Pfizer-BioNTech and Novavax, the other licensed manufacturers of coronavirus vaccines in the United States, are also developing combined vaccines, but Moderna is further along in releasing data.

Shares of Moderna Inc. fell sharply on Monday after the biotech firm projected a steep decline in 2025 revenues, falling below Wall Street expectations. The company, known for its COVID-19 vaccine ...

Moderna is set to receive $590m in funding from the HHS to expedite the development of mRNA-based pandemic influenza vaccines ...

Moderna's plans include a $1.1 billion reduction in R&D expenses by 2027 to a range of $3.6 billion to $3.8 billion. Rather than spending to explore new products, the company will shift its focus ...

Brooklyn Investment Group reduced its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 34.8% during the 4th quarter, ...

Fifteen European countries have secured an agreement with the American COVID-19 vaccine manufacturer Moderna through the European Commission f ...

Moderna gains HHS backing for developing mRNA-based pandemic influenza vaccines, advancing clinical studies for up to five subtypes. Get Pro-Level Earnings Insights Before the Market Moves Tuesday ...